Trainimal (TRML) Q1 24/25 earnings summary

Executive summary

• Net sales decreased by 2.7% to 2,629 TSEK compared to Q1 2023/2024, with a negative net result but positive EBITDA achieved for the first time.

• Consumer market remains challenging, but cost control and product development continue, with optimism for recovery in the remainder of 2024/2025.

• New app launch led to higher depreciation, impacting net results; marketing efforts to be intensified to grow user base.

• Margins remain strong, and new dietary supplements are performing as planned.

Financial highlights

• Net sales: 2,629 TSEK, down 2.7% year-over-year.

• Operating income (EBIT): -429 TSEK, down from 38 TSEK in Q1 2023/2024.

• EBITDA: 159 TSEK, down from 507 TSEK year-over-year.

• Net result before tax: -439 TSEK, compared to 21 TSEK last year.

• Earnings per share: -0.19 SEK, down from 0.01 SEK.

Outlook and guidance

• Signs of consumer market recovery expected to benefit operations in the coming quarters.

• Continued focus on cost control and marketing to expand the customer base.

• Management and board assess continued operations as secured based on liquidity and financing options.